The Russian pharmaceutical company Binnopharm Group and Vietnam’s VNVC have signed a memorandum of understanding, which involves the development of cooperation in drug production and distribution in Southeast Asian countries. The Vietnamese delegation, which included representatives from the Vietnamese Ministry of Health and the VNVC leadership, visited the Binnopharm Group’s research center laboratories. There, participants familiarized themselves with the center’s advanced drug developments, the domestic company’s press service told GxP News.
According to the memorandum, the companies plan to conduct joint research and development of medicines for the Vietnamese and Southeast Asian markets. VNVC will support Binnopharm Group with GMP certification, drug registration, and introduction to international markets.
“The signed memorandum creates new opportunities for our organizations. “We strive to share our technological solutions and accumulated experience to provide the people of Vietnam and other Southeast Asian regions with access to modern medicine,” commented Rustem Muratov, CEO of Binnopharm Group.
In turn, Ngo Chi Dung, chairman of the VNVC board of directors, added that the company’s cooperation will set an example for successful collaboration between countries aimed at improving the health of the entire region’s population.
In January 2025, it was announced that the Binnopharm Group had opened a representative office in Vietnam. At the time, Muratov noted that this country and others in Southeast Asia represented one of the fastest-growing segments of the pharmaceutical industry. In May, it was reported that a Russian company had also started work on drug registration in Indonesia.
